You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-PLL

Showing 1 - 25 of 8,011
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
  • Najing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Sep 26, 2022

T-Prolymphocytic Leukemia Trial in Duarte, Columbus, Houston (APG-115, APG-2575)

Recruiting
  • T-Prolymphocytic Leukemia
  • Duarte, California
  • +2 more
Jul 8, 2022

CLL, SLL, HCL Trial in Dresden

Recruiting
  • CLL
  • +7 more
    • Dresden, Sachsen, Germany
      BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
    Apr 29, 2022

    T-cell-prolymphocytic Leukemia Trial in Cologne (Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab)

    Completed
    • T-cell-prolymphocytic Leukemia
    • Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
    • Alemtuzumab
    • Cologne, Germany
      University Hospital Cologne
    Dec 16, 2021

    Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer Trial in Worldwide (Venetoclax, Ibrutinib)

    Completed
    Has Results
    • Leukemia
    • +2 more
    • Boston, Massachusetts
    • +14 more
    Nov 23, 2022

    Leukemia, MDS, Acute Myeloid Leukemia Trial in Houston (Cladribine)

    Not yet recruiting
    • Leukemia
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 28, 2023

    Lymphoma Trial in United States (Ruxolitinib)

    Recruiting
    • Lymphoma
    • Miami, Florida
    • +9 more
    Oct 5, 2022

    T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

    Not yet recruiting
    • T-Cell Non-Hodgkin Lymphoma
    • +14 more
    • WU-CART-007
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 17, 2023

    Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

    Recruiting
    • Recurrent Acute Lymphoblastic Leukemia
    • +15 more
    • Anti-CD19/CD20/CD22 CAR T-Cells
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 4, 2022

    Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial

    Active, not recruiting
    • Contiguous Stage II Small Lymphocytic Lymphoma
    • +11 more
    • MOR00208
    • +2 more
    • Columbus, Ohio
      The Ohio State University Comprehensive Cancer Center
    Feb 24, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial in Columbus (acalabrutinib,

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Columbus, Ohio
      Research Site
    Mar 11, 2022

    Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma Trial in Worldwide (Tinostamustine)

    Recruiting
    • Hematological Malignancies
    • +3 more
    • Phoenix, Arizona
    • +19 more
    Apr 12, 2022

    Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt

    Active, not recruiting
    • Prolymphocytic Leukemia
    • +4 more
    • Columbus, Ohio
    • +1 more
    Apr 29, 2022

    Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer Trial in Worldwide (CC-115)

    Completed
    • Glioblastoma Multiforme
    • +5 more
    • Los Angeles, California
    • +16 more
    Oct 4, 2021

    Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia Trial in Columbus (Romidepsin, Busulfan,

    Recruiting
    • Cutaneous T-cell Lymphoma
    • +4 more
    • Columbus, Ohio
      The Ohio State University Cancer Center
    Apr 18, 2022

    T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,

    Completed
    Has Results
    • T-Cell Lymphoma Relapsed
    • +4 more
    • IL-15 plus
    • alemtuzumab
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 27, 2022

    Periodontal Diseases Trial in Turin (Decontamination of the pocket with local doxycycline, Decontamination of the pocket with

    Recruiting
    • Periodontal Diseases
    • Decontamination of the pocket with local doxycycline
    • Decontamination of the pocket with mechanical instrumentation
    • Turin, Italy
      CIR Dental School
    May 17, 2023

    Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • CAR-T Therapy
    • Hefei, Anhui, China
    • +7 more
    Jul 31, 2023

    Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)

    Recruiting
    • Multiple Myeloma
    • APRIL-BAFF-Bicephali CAR-T cells
    • Xuzhou, Jiangsu, China
      Kailin Xu
    Nov 14, 2023

    Spinal Cord Injury Trial in Bronx (Natesto testosterone intranasal gel, Ayr Saline Nasal Gel)

    Not yet recruiting
    • Spinal Cord Injury
    • Natesto testosterone intranasal gel
    • Ayr Saline Nasal Gel
    • Bronx, New York
      James J. Peters VA Medical Center, Bronx, NY
    Nov 8, 2023

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

    Not yet recruiting
    • Acute Myeloid Leukemia, in Relapse
    • Acute Myeloid Leukemia Refractory
    • Cyclophosphamide (Non-IMP, Lymphodepletion)
    • +3 more
    • Ulm, Baden-Württemberg, Germany
    • +4 more
    Jul 24, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

    Recruiting
    • B Cell Malignancies
    • Universal CD19-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 8, 2023

    Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)

    Recruiting
    • Neoplasms
    • +3 more
    • RD13-02 cell infusion
    • Wuhan, Hubei, China
      Union Hospital, Huazhong University of Science and Technology
    Jun 8, 2023

    Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

    Recruiting
    • Advanced Breast Cancer
    • +2 more
    • Trastuzumab Emtansine (T-DM1)
    • Nanjing, Jiangsu, China
      JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
    Nov 5, 2023